NANOGAP Therapeutics 

Using a new class of chemical to treat currently untreatable cancer

OWNER

Ross Breckenridge (See Profile)

Sector

Biotech

Stage

Prototyping, preclinical

Country

Spain


A totally novel class of medicines, with novel mechanisms of action.

Our lead drug increases the effect of ROS in cancer cells without inducing ROS elsewhere

A novel method of treating KRAS-mutant cancers (around 30% of all cancers)

A broad range of indications and a pipeline of follow on drugs

Freely crosses the blood brain barrier, and into avascular cancers

This information is confidential, do not share or copy.

Under evaluation at least till: 22 May 2019

If you want to have more information or you want to review the project, you have to login or register

KEEP REVIEWING

©2019 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR
Aviso de cookies

Log in with your credentials

or    

Forgot your details?

Create Account

Skip to toolbar